Медицинская литература. Новинки

 

 

 

 

 

 

ПРОБЛЕМЫ ЗАМЕСТИТЕЛЬНОЙ ТЕРАПИИ ГИПОТИРЕОЗА: СОВРЕМЕННОСТЬ И ПЕРСПЕКТИВЫ

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Aoki Y., Belin R.M., Clickner R. et al. Serum TSH and total T4 in
the United States population and their association with participant
characteristics: National Health and Nutrition Examination
Survey (NHANES 1999–2002). Thyroid 2007; 17: 1211–1223.
2. Larsen P.R., Silva J.E., Kaplan M.M. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr. Rev. 1981; 2; 87–102.
3. Fadeyev V.V., Morgunova T.B., Sytsh J.P., Melnichenko G.A. TSH
and thyroid hormones concentrations in patients with hypothyroidism receiving replacement therapy with Lthyroxine alone
or in combination with Ltriiodthyronine. HORMONES 2005;
4 (2): 101–107.
4. Saravanan P., Chau W.F., Roberts N. et al. Psychological wellbeing in patients on adequate doses of Lthyroxine: results of
a large, controlled communitybased questionnaire study. Clin.
Endocrinol. (Oxf.) 2002; 57; 577–585.
5. Visser W.E., Friesema E.C., Visser T.J. Thyroid hormone transporters: the knowns and the unknowns. Mol. Endocrinol. 2011;
25: 1–14.
6. Zhang J., Lazar M.A. The mechanism of action of thyroid hormones. Ann. Rev. Physiol. 2000; 62: 439–466.
7. Ramadan W., Marsili A., Larsen P.R. et al. Type2 iodothyronine
5deiodinase in skeletal muscle of C57BL/6 mice. I. Identity, subcellular localization, and characterization. Endocrinology 2011;
152: 3082–3092.
8. Galton V.A. The roles of the iodothyronine deiodinases in mammalian development. Thyroid 2005; 15: 823–834.
9. Medina M.C., Molina J., Gadea Y. et al. The thyroid hormone-in-activating type III deiodinase is expressed in mouse and human β-cells and its targeted inactivation impairs insulin secretion.
Endocrinology 2011; 152: 3717–3727.
10. Huang S.A., Bianco A.C. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat. Clin. Pract.
Endocrinol. Metab. 2008; 4: 148–155.
11. Gullo D., Latina A., Frasca F. et al. Levothyroxine monotherapy
cannot guarantee euthyroidism in all athyreotic patients. PLoS
One 2011; 6: e22552.
12. Bianco A.C., Salvatore D., Gereben B. et al. Biochemistry, cellular
and molecular biology and physiological roles of the iodothyronine
selenodeiodinases. Endocr. Rev. 2002; 23: 38–89.
13. Schneider M.J., Fiering S.N., Pallud S.E. et al. Targeted disruption
of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of
pituitary resistance to T4. Mol. Endocrinol. 2001; 15: 2137–2148.
14. EscobarMorreale H.F., Obregón M.J., Escobar del Rey F.,
Morreale de Escobar G. Replacement therapy for hypothyroidism
with thyroxine alone does not ensure euthyroidism in all tissues, as
studied in thyroidectomized rats. J. Clin. Invest. 1995; 96:
2828–2838.
15. Andersen S., Bruun N.H., Pedersen K.M., Laurberg P. Biologic variation is important for interpretation of thyroid function tests.
Thyroid 2003; 13: 1069–1078.
16. Bianco A.C., Silva J.E. Cold exposure rapidly induces virtual saturation of brown adipose tissue nuclear T3 receptors. Am. J.
Physiol. 1988; 255: 496–503.
17. Dumitrescu A.M., Liao X.H., Abdullah M.S. et al. Mutations in
SECISBP2 result in abnormal thyroid hormone metabolism. Nat.
Gen. 2005; 37: 1247–1252.
18. Schneider M.J., Fiering S.N., Thai B. et al. Targeted disruption of
the type 1 selenodeiodinase gene (Dio1) results in marked changes
in thyroid hormone economy in mice. Endocrinology 2006; 147:
580–589.
19. Dayan C.M., Panicker V. Novel insights into thyroid hormones
from the study of common genetic variation. Nat. Rev. Endocrinol.
2009; 5: 211–218.
20. De Jong F.J., Peeters R.P., den Heijer T. et al. The association of
polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J. Clin. Endocrinol. Metab. 2007; 92: 636– 640.
21. Crantz F.R., Silva J.E., Larsen P.R. Analysis of the sources and
quantity of 3,5,3triiodothyronine specifically bound to nuclear
receptors in rat cerebral cortex and cerebellum. Endocrinology
1982; 110: 367–375.
22. Canani L.H., Capp C., Dora J.M. et al. The type 2 deiodinase A/G
(Thr92Ala) polymorphism is associated with decreased enzyme
velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2005; 90: 3472–3478.
23. Dora J.M., Machado W.E., Rheinheimer J. et al. Association of the
type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes:
casecontrol study and metaanalysis. Eur. J. Endocrinol. 2010;
163: 427–434.
24. Guo T.W., Zhang F.C., Yang M.S. et al. Positive association of the
DIO2 (deiodinase type 2) gene with mental retardation in the
iodinedeficient areas of China. J. Med. Genet. 2004; 41: 585–590.
25. Gumieniak O., Perlstein T.S., Williams J.S. et al. Ala92 type 2 deiodinase allele increases risk for the development of hypertension.
Hypertension 2007; 49: 461–466.
26. Meulenbelt I., Min J.L., Bos S. et al. Identification of DIO2 as new
susceptibility locus for symptomatic osteoarthritis. Hum. Mol.
Genet. 2008; 17: 1867–1875.
27. He B., Li J., Wang G. et al. Association of genetic polymorphisms
in the type II deiodinase gene with bipolar disorder in a subset of
Chinese population. Prog. Neuropsychopharmacol. Biol.
Psychiatry. 2009; 33: 986–990.
28. Torlontano M., Durante C., Torrente I. et al. Type 2 deiodinase
polymorphism (Thr92Ala) predicts Lthyroxine dose to achieve
target TSH levels in thyroidectomized patients. J. Clin.
Endocrinol. Metab. 2008; 93: 910–913.
29. Butler P.W., Smith S.M., Linderman J.D. et al. The Thr92Ala
5type 2 deiodinase gene polymorphism is associated with
a delayed triiodothyronine secretion in response to the thyrotropinreleasing hormonestimulation test: a pharmacogenomic
study. Thyroid. 2011; 20: 1407–1412.
30. Ng L., Lyubarsky A., Nikonov S.S. et al. Type 3 deiodinase, a thyroidhormoneinactivating enzyme, controls survival and maturation of cone photoreceptors. // J. Neurosci. 2010; 30: 3347–3357.
31. Mohacsik P., Zeold A., Bianco A.C., Gereben B. Thyroid hormone
and the neuroglia: both source and target. J. Thyroid. Res. 2011;
2011: 215718.
32. Dumitrescu A.M., Liao X.H., Best T.B. et al. A novel syndrome
combining thyroid and neurological abnormalities is associated
with mutations in a monocarboxylate transporter gene. Am. J.
Hum. Genet. 2004; 74: 168–175.
33. Sugiyama D., Kusuhara H., Taniguchi H. et al. Functional characterization of rat brainspecific organic anion transporter (Oatp14)
at the bloodbrain barrier: high affinity transporter for thyroxine.
J. Biol. Chem. 2003; 278: 43489–43495.
34. Van der Deure W., Appelhof B.C., Peeters R.P. et al. Polymorphism
in the brainspecific thyroid hormone transporter OATP-C1 are
associated with fatigue and depression in hypothyroid patients.
Clin. Endocrinol. 2008; 69: 804–811.
35. Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The
Colorado thyroid disease prevalence study. Arch. Intern. Med.
2000; 28: 526–534.
36. Katon W., Schulberg H. Epidemiology of depression in primary
care. Gen Hosp. Psychiatry 1992; 14: 237–247.
37. Paunkovic N., Paunkovic J., Pavlovic O., Paunovic Z. The significant increase in incidence of Graves' disease in eastern Serbia during the civil war in the former Yugoslavia (1992 to 1995). Thyroid.
1998; 8: 37–41.
38. Louwerens M., Appelhof B.C., Verloop H. et al. Fatigue and fatiguerelated symptoms in patients treated for different causes of hypothyroidism. Eur. J. Endocrinol. 2012; Sep (in press).
39. Walsh J. P., Ward L. C., Burke V. et al. Small changes in thyroxine
dosage do not produce measurable changes in hypothyroid symptoms, wellbeing, or quality of life: results of a double-blind, randomized clinical trial. J. Clin. Endocrinol. Metab. 2006; 91:
2624–2630.
40. Подзолков А.В., Фадеев В.В. Оценка динамики показателей
липидного спектра и ранних предикторов эндотелиальной
дисфункции при первичным гипотиреозе в зависимости от
уровня ТТГ в пределах референсного диапазона. Клин.
и экспер. тиреоидол. 2010; 3: 54–59.
41. Подзолков А.В., Фадеев В.В. Высоко и низконормальный
уровень ТТГ: клиническая картина, психоэмоциональная
сфера и качество жизни пациентов с гипотиреозом. Клин.
и экспер. тиреоидол. 2010; 4: 58–68.
42. Bunevicius R., Kazanavicius G., Zalinkevicius R., Prange A.J.
Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. Engl. J. Med. 1999; 340:
424–429.
43. Bunevicius R., Jakubonien N., Jurkevicius R. et al. Thyroxine vs.
thyroxine plus triiodothyronine in treatment of hypothyroidism
after thyroidectomy for Graves’ disease. Endocrine 2002; 18:
129–133.
44. Nygaard B., Jensen E.W., Kvetny J. et al. Effect of combination
therapy with thyroxine (T4) and 3,5,3triiodothyronine versus T4
monotherapy in patients with hypothyroidism, a double-blind,
randomised crossover study. Eur. J. Endocrinol. 2009; 161:
895–902.
45. GrozinskyGlasberg S., Fraser A., Nahshoni E. et al. Thyroxine-tri-iodothyronine combination therapy versus thyroxine monotherapy
for clinical hypothyroidism: metaanalysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 2006; 91: 2592–2599.
46. Garber J.R., Cobin R.H., Gharib H. et al. Clinical Practice
Guidelines for Hypothyroidism in Adults: Cosponsored by the
American Association of Clinical Endocrinologists and the
American Thyroid Association. Endocr. Pract. 2012; 11: 1–207.
47. Wiersinga W., Duntas L., Fadeyev V. et al. The Use of L-T4 + L-T3
in the Treatment of Hypothyroidism. Eur. Thyroid. J. 2012; 1:
55–71.
48. Фадеев В.В. По материалам клинических рекомендаций
Европейской тиреоидной ассоциации по использованию
комбинированной терапии LT4 + LT3 в лечении
гипотиреоза. Клин. и экспер. тиреоидол. 2012; 2: 14–18.
49. Fadeyev V.V., Morgunova T.B., Melnichenko G.A., Dedov I.I.
Combined therapy with LThyroxine and LTriiodothyronine
compared to LThyroxine alone in the treatment of primary
hypothyroidism. Hormones (Athens) 2010; 9: 245–252.
50. Panicker V., Saravanan P., Vaidya B. et al. Common variation in
the DIO2 gene predicts baseline psychological wellbeing and
response to combination thyroxine plus triiodothyronine therapy
in hypothyroid patients. J. Clin. Endocrinol. Metab. 2009; 94:
1623–1629.
51. Hollowell J.G., Staehling N.W., Flanders W.D. et al. Serum TSH,
T(4), and thyroid antibodies in the United States population (1988
to 1994): National Health and Nutrition Examination Survey
(NHANES III). J. Clin. Endocrinol. Metab. 2002; 87: 489–499.
52. Völzke H., Schmidt C.O., John U. et al. Reference levels for serum
thyroid function tests of diagnostic and prognostic significance.
Horm. Metab. Res. 2010; 42: 809–814.
53. Фадеев В.В., Берковская М.А., Мельниченко Г.А. Результаты
опроса эндокринологов по проблемам нарушения функции
щитовидной железы. Клин. и экспер. тиреоидол. 2008; 2:
41–47.
54. Свиридонова М.А., Фадеев В.В., Ильин А.В. Циркадианная и
индивидуальная вариабельность уровня ТТГ и тиреоидных
гормонов у лиц с субклиническим гипотиреозом. Клин.
и экспер. тиреоидол. 2010; 3: 35–41.
55. Свиридонова М.А., Ильин А.В., Фадеев В.В. Циркадианная
и индивидуальная вариабельность уровня ТТГ у лиц,
получающих заместительную терапию гипотиреоза. Клин.
и экспер. тиреоидол. 2010; 4: 52–57.
56. Свиридонова М.А., Ильин А.В., Фадеев В.В. Циркадианная
вариабельность уровня ТТГ на фоне супрессивной терапии
левотироксином. Клин. и экспер. тиреоидол. 2011; 1: 55–57.
57. StagnaroGreen A., Abalovich M., Alexander E. et al. Guidelines of
the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and postpartum.
Thyroid. 2011; 21 (21): 1081–1125.
58. Фадеев В.В. По материалам клинических рекомендаций по
диагностике и лечению заболеваний щитовидной железы во
время беременности и в послеродовом периоде Американской тиреоидной ассоциации. Клин. и экспер. тиреоидол.
2012; 1: 7–18.
59. De Groot L., Abalovich M., Alexander E.K. et al. Management of
thyroid dysfunction during pregnancy and postpartum: an
Endocrine Society clinical practice guideline. J. Clin. Endocrinol.
Metab. 2012, 97: 2543–2565.

Challenges in replacement therapy of hypothyroidism: everyday practice and perspectives

Keywords: